Skip to Content


Active Substance: cidofovir
Common Name: cidofovir
ATC Code: J05AB12
Marketing Authorisation Holder: Gilead Sciences International Limited
Active Substance: cidofovir
Status: Withdrawn
Authorisation Date: 1997-04-23
Therapeutic Area: Cytomegalovirus Retinitis
Pharmacotherapeutic Group: Antivirals for systemic use

Therapeutic Indication

Vistide is indicated for the treatment of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome (AIDS) and without renal dysfunction. Vistide should be used only when other agents are considered unsuitable.

The marketing authorisation for Vistide has been withdrawn at the request of the marketing authorisation holder.

Source: European Medicines Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.